Myles just posted on Twitter16 Nov 2021 09:50
t's been a painful year, SP-wise, for @avacta.
From over +150% YTD in March, to 7% down now.
However, my faith in #AVCT gaining legendary status has only grown.
Critical RNSs of 2021:
1) HUA in the EU for AffiDX;
2) First dose escalation for AVA6K.
Both imminent, IMO
The first item will be the catalyst for the commencement of major cash flows for #AVCT.
Having HUA in the EU will facilitate (and accelerate) the granting of HUA in numerous other territories.
The recent independent study will also be a godsend for marketing purposes.
That study demonstrated that AffiDX had 100% sensitivity (up to CT28) and 100% specificity - putting it in the top handful of tests worldwide.
Many countries are phasing out free #COVID19 LFTs. Germany last month, UK to be in Q1.
But COVID-19 is unfortunately here to stay
When people are buying tests themselves (esp. to see older family members), the cream will rise (provided of course that the cream is cost competitive!).
With @Abingdon_Health #ABDX also set to come online for #AVCT any day now, supply can really be ramped up to meet demand
There is also international manufacturing capacity in place (up to 30m a month) - IF @medusa19_ and @avacta can generate sufficient demand.
And of course, there is the rumored proprietary capacity of Medusa itself.????
HUA lands: it all kicks off for #AVCT, I really believe
AVA6K: I think #AVCT is almost at the end of - or has just completed - the 21 observation period, following the third dose of the third patient in C1.
IF all has gone well, dose escalation / commencement of C2 will be a mammoth indicator for both the market and the industry
I know a great many have exited in recent months.
For me, #AVCT right now is a classic example of:
"It's always darkest before the dawn."
The work going on behind the scenes has been immense, I have no doubt.
Buzzing to see how it all plays out in the coming weeks
Sign In
Follow the stocks
